样式: 排序: IF: - GO 导出 标记为已读
-
Social Determinants of Health and the Link to Colorectal Cancer Outcomes Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-03-18 Michael K. Lorentsen, Hanna K. Sanoff
Colorectal cancer (CRC) remains the second most deadly cancer in the United States, behind only lung cancer. Despite improvements in incidence due to screening and mortality in part due to better treatments, there are some groups that have not seen these promising changes. American Indian/Alaska Native and non-Hispanic Black individuals, certain geographic regions, and lower socioeconomic groups have
-
Update on Dosing and Fractionation for Neoadjuvant Radiotherapy for Localized Soft Tissue Sarcoma Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-03-13 Siyer Roohani, Lisette M. Wiltink, David Kaul, Mateusz Jacek Spałek, Rick L. Haas
Neoadjuvant radiotherapy (RT) over 5–6 weeks with daily doses of 1.8–2.0 Gy to a total dose of 50–50.4 Gy is standard of care for localized high-grade soft tissue sarcomas (STS) of the extremities and trunk wall. One exception is myxoid liposarcomas where the phase II DOREMY trial applying a preoperative dose of 36 Gy in 2 Gy fractions (3–4 weeks treatment) has achieved excellent local control rates
-
Ovarian Suppression: Early Menopause and Late Effects Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-03-13 Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Roberto Borea, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Cynthia Villarreal-Garza, Jyoti Bajpai, Hee Jeong Kim, Silvia Puglisi, Evandro de Azambuja, Matteo Lambertini
-
Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-03-12 Tali Pomerantz, Rebecca Brooks
Circulating tumor DNA (ctDNA) refers to small fragments of DNA released into the bloodstream by cancer cells. It is obtained through “liquid biopsy;" which most commonly refers to plasma or blood samples, but can be obtained from a number of bodily fluids including ascitic fluid, saliva, and even urine and stool. ctDNA is detected via polymerase chain reaction (PCR) or next-generation sequencing (NGS)
-
Neoadjuvant Short- Vs. Long-Course Radiation for Locally Advanced Rectal Cancer: How to Choose Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-22 Christopher G. Willett, Scarlett Acklin-Wehnert
Over the past decades, the treatment of locally advanced rectal cancer has evolved dramatically due to improvements in diagnostic imaging, surgical technique, and the addition of radiotherapy and/or chemotherapy. Fractionation of neoadjuvant radiotherapy with or without concurrent chemotherapy remains the subject of discussion and the question multiple recent trials have aimed to answer. In light of
-
Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer? Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-19 Suhaib Khateeb, Ludimila Cavalcante, Noor Alnairat, Meghana Singh, Ibrahim Halil Sahin, Azhar Saeed, Anwaar Saeed
-
A Comprehensive Review of Cancer Drug–Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-19 Vincenzo Costanzo, Yashwant Kumar Ratre, Emanuela Andretta, Rakesh Acharya, L. V. K. S. Bhaskar, Henu Kumar Verma
-
Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand? Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-17 Sietske C. M. W. van Nassau, Guus M. Bol, Frederieke H. van der Baan, Jeanine M. L. Roodhart, Geraldine R. Vink, Cornelis J. A. Punt, Anne M. May, Miriam Koopman, Jeroen W. G. Derksen
-
Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-14 Herbert B. Newton, Jenna Wojkowski
Seizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor–related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in
-
Preoperative Strategies for Locally Advanced Colon Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-13 Kanika G. Nair, Suneel D. Kamath, Nivan Chowattukunnel, Smitha S. Krishnamurthi
Neoadjuvant chemotherapy is safe for patients with locally advanced colon cancer (LACC). The FOxTROT trial demonstrated a reduction in residual and recurrent cancer at 2 years with neoadjuvant chemotherapy for patients with cT3-4 LACC. Preoperative chemotherapy should be avoided, if possible, for patients with dMMR LACC, as over 50% of dMMR cancers have no pathologic response. Early universal testing
-
A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-07 Rita Khoury, Tarek Assi, Rebecca Ibrahim, Tony Ibrahim, Benjamin Verret, Clemence Henon, Ratislav Bahleda, Axel Le Cesne
Soft tissue sarcoma (STS), a substantial group of aggressive and rare tumors with tissue heterogeneity, is infrequently represented in clinical trials with an urgent necessity for newer treatment options. Lurbinectedin, an analog of trabectedin, is currently approved, in various countries, as a single agent, for the treatment of patients with relapsed small cell lung cancer (SCLC). However, preclinical
-
One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-05
Opinion Statement Urothelial carcinoma is the predominant cancer of the urinary tract but when divergent and subtype histology (non-urothelial) are identified at time of pathologic diagnosis, therapeutic and diagnostic challenges transpire. To this end, pathologic review to confirm any non-urothelial histology is key since these subtypes can often be overlooked. Few prospective trials are dedicated
-
Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-01 David Gritsch, Sandro Santagata, Priscilla K. Brastianos
The integration of targeted therapy into the multimodal management of craniopharyngiomas represents a significant advancement in the field of neuro-oncology. Historically, the management of these tumors has been challenging due to their proximity to vital brain structures, necessitating a delicate balance between tumor control and the preservation of neurological function. Traditional treatment modalities
-
Evaluation of Homologous Recombination Deficiency in Ovarian Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-02-01 Rubina Ratnaparkhi, Melissa Javellana, Andrea Jewell, Lori Spoozak
Homologous recombination deficiency (HRD) is an important biomarker guiding selection of ovarian cancer patients who will derive the most benefit from poly(ADP-ribose) polymerase inhibitors (PARPi). HRD prevents cells from repairing double-stranded DNA damage with high fidelity, PARPis limit single-stranded repair, and together these deficits induce synthetic lethality. Germline or somatic BRCA mutations
-
Research Progress on the Use of Metformin in Leukemia Treatment Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-30 Qian Wang, Xudong Wei
-
Impact of PSMA PET on Prostate Cancer Management Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-25 Adam B. Weiner, Raag Agrawal, Luca F. Valle, Ida Sonni, Amar U. Kishan, Matthew B. Rettig, Steven S. Raman, Jeremie Calais, Paul C. Boutros, Robert E. Reiter
PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution
-
Desmoid Tumors: Current Perspective and Treatment Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-25
Opinion statement Desmoid tumors are rare tumors with a tendency to infiltrate locally. The lack of a standard treatment approach makes choosing the most appropriate treatment for patients challenging. Most experts recommend watchful observation for asymptomatic patients as spontaneous regression of tumor is observed in up to 20% of patients. Upfront resection of the desmoid tumor has fallen out of
-
Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-10 Maxime Junior Jean, Lawrence Samkoff, Nimish Mohile
Our understanding of paraneoplastic neurologic syndromes (PNS) has blossomed over the past few decades. Clinicians have access to more robust diagnostic criteria and have a heightened index of suspicion for these disorders. Nonetheless, treatment, which typically includes immunosuppression, and response to treatment, varies. Due to persistent difficulty in making a definitive diagnosis, we favor empiric
-
Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-05 Margaret Wheless, Rajiv Agarwal, Laura Goff, Natalie Lockney, Chandrasekhar Padmanabhan, Thatcher Heumann
-
Sentinel Lymph Node Evaluation in Early-Stage Vulvar Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-03 Courtney A. Penn, Mali K. Schneiter, Catherine H. Watson
Sentinel lymph node mapping (SLNM) and dissection (SLND) should be used as an alternative to full inguinofemoral lymph node dissection (IFLND) in select patients with early-stage vulvar cancer. IFLND is associated with high postoperative complications such as wound breakdown, lymphedema, lymphocyst formation, and infection. SLND in select patients offers a safe, effective, and less morbid alternative
-
Approach to Patients with High-Risk Localized Prostate Cancer: Radiation Oncology Perspective Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-03 Sophia C. Kamran, Neha Vapiwala
High-risk localized prostate cancer is a challenging clinical entity to treat, with heterogeneous responses to an evolving array of multidisciplinary treatment approaches. In addition, this disease state is growing in incidence due to a variety of factors, including shifting recommendations that discouraged routine prostate cancer screening. Current guidelines now incorporate an informed decision-making
-
Antibody-Drug Conjugates in Gynecologic Cancers Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-03 Mary Katherine Anastasio, Stephanie Shuey, Brittany A. Davidson
-
Targeting BRCA and PALB2 in Pancreatic Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-04 Sriram Anbil, Kim A. Reiss
An important subgroup of pancreatic ductal adenocarcinomas (PDACs) harbor pathogenic variants in BRCA1, BRCA2, or PALB2. These tumors are exquisitely sensitive to platinum-based chemotherapy and patients may experience deep and durable responses to this treatment. PARP inhibitors offer potential respite from the cumulative toxicities of chemotherapy as they significantly extend progression-free survival
-
Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-04 Anthony V. Serritella, Maha Hussain
Treatment for metastatic hormone–sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including
-
Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-04 Elizabeth A. Tubridy, Neil K. Taunk, Emily M. Ko
The standard of treatment for node-positive endometrial cancer (FIGO Stage IIIC) in North America has been systemic therapy with or without additional external beam radiation therapy (RT) given as pelvic or extended field RT. However, this treatment paradigm is rapidly evolving with improvements in systemic chemotherapy, the emergence of targeted therapies, and improved molecular characterization of
-
Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-04
Opinion statement In our clinical practice, we have shifted away from the use of adjuvant normothermic intraperitoneal (IP) chemotherapy, particularly following the publication of GOG 252. Our decision is rooted in the accumulating evidence indicating a lack of demonstrable superiority, alongside the recognized toxicities and logistical challenges associated with its administration. This strategic
-
Hypnosis for Symptom Management in Adult Cancer Patients: What is the Evidence? Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-04 Petra Vayne-Bossert
As a palliative care specialist and a hypnotherapist, I use therapeutic communication and conversational hypnosis daily in my patient – doctor relationship. Formal hypnotherapy sessions are integrated in my practice whenever patients are open or wish for such an approach in relation to a specific symptom, for better overall management of their disease burden and/or enhanced well-being. Although hypnosis
-
Therapeutic Management of Malignant Wounds: An Update Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-04 Adelina-Gabriela Niculescu, Mihaela Georgescu, Ioana Cristina Marinas, Cem Bulent Ustundag, Gloria Bertesteanu, Mariana Pinteală, Stelian Sergiu Maier, Cristina Maria Al-Matarneh, Marian Angheloiu, Mariana Carmen Chifiriuc
-
Updates on Management of Biochemical Recurrent Prostate Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-03 Lauren Folgosa Cooley, Abhishek Srivastava, Neal D. Shore
Patients with biochemical recurrent prostate cancer (BCR) are a heterogeneous group, whereby a personalized approach to management is critical. Patients with high-risk features such as PSA doubling time (PSADT) ≤ 9–12 months warrant earlier imaging for metastasis detection and consideration for intensified therapy (beyond intermittent androgen deprivation alone) during this phase of BCR-only disease
-
Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider? Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-03 Emma-Anne Karlsen, Euan Walpole, Fiona Simpson
-
Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-03
Opinion statement Localized high-risk (HR) prostate cancer (PCa) is a heterogenous disease state with a wide range of presentations and outcomes. Historically, non-surgical management with radiotherapy and androgen deprivation therapy was the treatment option of choice. However, surgical resection with radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is increasingly utilized as a
-
Strategies to Assess and Manage Frailty among Patients Diagnosed with Primary Malignant Brain Tumors Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2024-01-03 Alayna E. Ernster, Heidi D. Klepin, Glenn J. Lesser
Frailty refers to a biologic process that results in reduced physiologic and functional reserve. Patients diagnosed with primary malignant brain tumors experience high symptom burden from tumor and tumor-directed treatments that, coupled with previous comorbidities, may contribute to frailty. Within the primary malignant brain tumor population, frailty is known to associate with mortality, higher healthcare
-
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-30 Wendy J. Sherman, Edoardo Romiti, Loizos Michaelides, Diogo Moniz-Garcia, Kaisorn L. Chaichana, Alfredo Quiñones-Hinojosa, Alyx B. Porter
Melanoma has a high propensity to metastasize to the brain which portends a poorer prognosis. With advanced radiation techniques and targeted therapies, outcomes however are improving. Melanoma brain metastases are best managed in a multi-disciplinary approach, including medical oncologists, neuro-oncologists, radiation oncologists, and neurosurgeons. The sequence of therapies is dependent on the number
-
Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-28 Yinan Yu, Jianguo Zhao, Jiaona Xu, Rui Bai, Zewei Gu, Xialin Chen, Jianfang Wang, Xueying Jin, Gaoyang Gu
-
Treatment Landscape of Renal Cell Carcinoma Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-28 Yu-Wei Chen, Luke Wang, Justine Panian, Sohail Dhanji, Ithaar Derweesh, Brent Rose, Aditya Bagrodia, Rana R. McKay
The treatment landscape of renal cell carcinoma (RCC) has evolved significantly over the past three decades. Active surveillance and tumor ablation are alternatives to extirpative therapy in appropriately selected patients. Stereotactic body radiation therapy (SBRT) is an emerging noninvasive alternative to treat primary RCC tumors. The advent of immune checkpoint inhibitors (ICIs) has greatly improved
-
Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-15
Opinion statement The treatment of neuroendocrine neoplasm (NEN) liver metastases involves a multidisciplinary approach that includes liver-directed therapies (LDT) and systemic treatments, such as peptide receptor radionuclide therapy (PRRT). LDT has demonstrated efficacy in rapidly reducing tumor bulk, improving symptoms, and delaying disease progression. Interventional radiologists should be consulted
-
Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-14 Qingyu Zeng, Chengqian Chen, Diyan Chen, Guolong Zhang, Xiuli Wang
-
Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-14 Leah Wells, Angel Qin
EGFR tyrosine kinase inhibitors (TKI) should always be considered when treating advanced/metastatic non-small cell lung cancer (NSCLC) with atypical EGFR mutations. The first choice of TKI depends on the specific mutation(s) present and its effect on structure and function of the EGFR protein. Afatinib is the only EGFR TKI currently FDA approved for atypical EGFR mutations and has the strongest data
-
Extent of Resection and Outcomes of Patients with Primary Malignant Brain Tumors Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-13 Brandy Ndirangu, Kevon Bryan, Edjah Nduom
We have level II evidence that attempting a gross total resection of newly diagnosed suspected glioblastoma is preferred when a maximally safe resection can be attempted. This recommendation extends to elderly patients and those with butterfly gliomas. However, in cases where patients are poor surgical candidates, or for lesions in eloquent areas, subtotal resection or biopsy may be indicated. Recent
-
Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-13 Rebekah Summey, Rana Aliani, Lindsey A. McAlarnen, Nicole Sequeira, Tahseen Shaik, Denise Uyar, Sherry-Ann Brown
-
Perioperative Immunotherapy in Non-Small Cell Lung Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-13 Jenny O’Brien, J. Nicholas Bodor
The standard of care in patients with early-stage non-small cell lung cancer (NSCLC) following surgical resection has been adjuvant chemotherapy for the last two decades, despite modest improvements in survival and high rates of disease recurrence. Numerous clinical trials have reported practice-changing findings demonstrating a benefit in disease-free survival (DFS) or event-free survival (EFS) with
-
Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer – An Overview Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-11 Aleksandra Tarasiuk, Grzegorz Mirocha, Jakub Fichna
Pancreatic cancer (PC) remains the deadliest cancer worldwide. Most patients are diagnosed at the advanced or metastatic stage, leading to a poor prognosis. Awareness of the limitations of current therapy and accompanying pain, depression, malnutrition, and side effects of chemoradiotherapy may lead patients and physicians towards complementary and alternative medicine (CAM). CAM refers to a diverse
-
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-12-04 Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Paolo Spallarossa, Francesco Passamonti
-
The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-11-22 Laura Mariën, Odeta Islam, Siddharth Chhajlani, Willem Lybaert, Marc Peeters, Guy Van Camp, Ken Op de Beeck, Timon Vandamme
-
The Evolving Treatment Landscape of Medullary Thyroid Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-11-18 Marta Laganà, Valentina Cremaschi, Andrea Alberti, Danica M. Vodopivec Kuri, Deborah Cosentini, Alfredo Berruti
-
Updates in Management of Malignant Pleural Mesothelioma Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-11-17 Alexius John, Hazel O’Sullivan, Sanjay Popat
-
Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-11-15 Oluwadunni E. Emiloju, Mojun Zhu, Hao Xie, Zhaohui Jin, Frank A. Sinicrope, Joleen M. Hubbard
-
Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-11-14 Ping Li, Linan Jia, Xiaobo Bian, Shutao Tan
-
Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-11-08 Qi-An Wang, Huan-Wu Chen, Ren-Chin Wu, Chiao-En Wu
-
Frontiers of Ovarian Carcinosarcoma Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-11-08 Ayden Ismail, Sunyoung Choi, Stergios Boussios
Ovarian carcinosarcoma (OCS), also known as a malignant mixed Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts for less than 5% of ovarian cancers. It is characterized by high morbidity and mortality rates, with a median overall survival (OS) of less than 2 years. Several factors, including advancing age, nulliparity, reduced lactation rates, decreased use of oral contraceptive
-
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-10-25 Malwina Stanowicka-Grada, Elżbieta Senkus
Approximately 15–20% of breast cancers (BC) demonstrate HER2 overexpression/gene amplification. Historically, before the era of HER2-directed therapies, this subtype was associated with poor prognosis. Anti-HER2 agents dramatically changed the natural course of disease and significantly prolonged patients’ survival. In recent years, a number of new anti-HER2 therapies have been developed, and their
-
The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-10-26 Davide Citterio, Jorgelina Coppa, Carlo Sposito, Michele Droz Dit Busset, Matteo Virdis, Isabella Pezzoli, Vincenzo Mazzaferro
-
Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-10-23 Shujing Guo, Xuejin Gao, Mahara Sadhana, Ruiting Guo, Jile Liu, Wenyi Lu, Ming Feng Zhao
-
Sequencing Systemic Therapy in Hepatocellular Carcinoma Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-10-16 Ben Ponvilawan, Marc T. Roth
-
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-10-16 Tarek Assi, Carine Ngo, Matthieu Faron, Benjamin Verret, Antonin Lévy, Charles Honoré, Clémence Hénon, Cécile Le Péchoux, Rastilav Bahleda, Axel Le Cesne
The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear recommendations or specific guidelines. In the advanced setting, specific systemic therapy such as eribulin and trabectedin
-
Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-10-09 Zhuocheng Xin, Qi Liu, Dashan Ai, Ke Chen, Elene Mariamidze, Mostafa Aziz Sumon, Bharti Devnani, Rille Pihlak, Hongcheng Zhu, Kuaile Zhao
Esophageal cancer is a global health problem, which is 7th most common and 6th most deadly cancer. It has been the era of immuno-oncology for esophageal cancer management. Radiation therapy has been one of the key local therapeutic approaches for esophageal cancer treatment, while its role in advanced disease is challenging and debatable. There have been emerging clinical and translational studies
-
Optimal Therapeutic Strategy for PD-L1 Negative Metastatic Non-Small Cell Lung Cancer: A Decision-Making Guide Based on Clinicopathological and Molecular Features Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-10-06 Mariana Malvicini, Maysa Silveira Vilbert, José N. Minatta, Valeria Colomo Costas, Manglio M. Rizzo
-
Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-09-20 Sebastian F. Winter, Eugene J. Vaios, Helen A. Shih, Clemens Grassberger, Michael W. Parsons, Melissa M. Gardner, Felix Ehret, David Kaul, Wolfgang Boehmerle, Matthias Endres, Jorg Dietrich
-
The Crying Need for a Better Response Assessment in Rectal Cancer Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-09-13 Samuel Amintas, Nicolas Giraud, Benjamin Fernandez, Charles Dupin, Quentin Denost, Aurelie Garant, Nora Frulio, Denis Smith, Anne Rullier, Eric Rullier, Te Vuong, Sandrine Dabernat, Véronique Vendrely
-
Opioid-induced Neurotoxicity in Patients with Cancer Pain Curr. Treat. Options Oncol. (IF 4.3) Pub Date : 2023-09-09 Sebastiano Mercadante
Opioid-induced neurotoxicity (OINT) is a neuropsychiatric syndrome observed with opioid therapy. The mechanism of OINT is thought to be multifactorial, and many risk factors may facilitate its development. If symptoms of OINT are seen, the prescriber should consider hydration, discontinuation of the offending opioid drug, or switching of opioid medication, or the use of some adjuvants. Multiple factors